[SaneVax: Norway’s Vaccibody is in the process of developing a therapeutic vaccine for treatment of CIN 1 or 2 lesions associated with HPV 16. They anticipate being ready for clinic by 2013. The question is, why are they even developing a vaccine to treat lesions that normally clear on their own? When is the pharmaceutical industry going to understand the simple concept that if it’s not broken, you don’t need to fix it?]
HPV DNA vax should enter the clinic in 2013
By Suzanne Edvidge, Fierce Vaccines
Vaccibody’s DNA plasmids are designed to treat pre-cancerous changes caused by HPV
Vaccibody’s lead therapeutic DNA vaccine, developed for the treatment of precancerous changes in the cervix caused by human papillomavirus (HPV) infection, is expected to move into the clinic in late 2013 once funding is in place, the company CEO Ole Henrik Brekke told FierceVaccines at BIO 2012. The trial will recruit women who are infected with HPV-16 and have cervical intraepithelial neoplasia (CIN) at grade 1 or 2.
The Norwegian vaccine company has designed the vaccine to trigger a T cell response in a single shot by targeting the dendritic cells (also known as antigen-presenting cells). The HPV vaccine is administered just under the skin or into the muscle using electroporation technology, where a small charge allows the plasmid (a small circle of coding DNA) into the cell. The genetic information then harnesses the cell’s manufacturing capabilities to create the three-component protein vaccine.
HPV DNA vax should enter the clinic in 2013 – FierceVaccines : Read the entire article here.